File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)
  • Basic View
  • Metadata View
  • XML View
TitleProteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)
 
AuthorsSun, S2
Poon, RTP2
Lee, NP2
Yeung, C2
Chan, KL2
Ng, IOL2
Day, PJR1
Luk, JM2 3 3
 
KeywordsAFP
Biomarker
Cancer screening
HCC
Tumor detection
Tumor size
 
Issue Date2010
 
PublisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs
 
CitationJournal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930 [How to Cite?]
DOI: http://dx.doi.org/10.1021/pr901085z
 
AbstractSmall hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society.
 
ISSN1535-3893
2012 Impact Factor: 5.056
2012 SCImago Journal Rankings: 1.657
 
DOIhttp://dx.doi.org/10.1021/pr901085z
 
ISI Accession Number IDWOS:000276215700028
Funding AgencyGrant Number
Research Grants Council of Hong Kong771607M
National Medical Research Council
Funding Information:

The work was supported by grants from the Research Grants Council of Hong Kong (771607M) and National Medical Research Council to J.M.L. We also thank for the generous donation from the Sun Chien Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery. We sincerely acknowledge Dr. W. C. Yu for giving clinical assistance in specimen collection and preparation. We also thank Dr. Wilson Y.P. Ching in Department of Anatomy, The University of Hong Kong for providing the monoclonal vimentin antibody in our preliminary studies. Irene Ng is Loke Yew Professor of Pathology.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorSun, S
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorLee, NP
 
dc.contributor.authorYeung, C
 
dc.contributor.authorChan, KL
 
dc.contributor.authorNg, IOL
 
dc.contributor.authorDay, PJR
 
dc.contributor.authorLuk, JM
 
dc.date.accessioned2010-09-06T09:43:54Z
 
dc.date.available2010-09-06T09:43:54Z
 
dc.date.issued2010
 
dc.description.abstractSmall hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (≤2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (≤2 cm) with p < 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p < 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. © 2010 American Chemical Society.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930 [How to Cite?]
DOI: http://dx.doi.org/10.1021/pr901085z
 
dc.identifier.doihttp://dx.doi.org/10.1021/pr901085z
 
dc.identifier.epage1930
 
dc.identifier.hkuros169635
 
dc.identifier.isiWOS:000276215700028
Funding AgencyGrant Number
Research Grants Council of Hong Kong771607M
National Medical Research Council
Funding Information:

The work was supported by grants from the Research Grants Council of Hong Kong (771607M) and National Medical Research Council to J.M.L. We also thank for the generous donation from the Sun Chien Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery. We sincerely acknowledge Dr. W. C. Yu for giving clinical assistance in specimen collection and preparation. We also thank Dr. Wilson Y.P. Ching in Department of Anatomy, The University of Hong Kong for providing the monoclonal vimentin antibody in our preliminary studies. Irene Ng is Loke Yew Professor of Pathology.

 
dc.identifier.issn1535-3893
2012 Impact Factor: 5.056
2012 SCImago Journal Rankings: 1.657
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid20121168
 
dc.identifier.scopuseid_2-s2.0-77950647292
 
dc.identifier.spage1923
 
dc.identifier.urihttp://hdl.handle.net/10722/88478
 
dc.identifier.volume9
 
dc.languageeng
 
dc.publisherAmerican Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/jprobs
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Proteome Research
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshCarcinoma, Hepatocellular - blood - diagnosis - pathology
 
dc.subject.meshLiver Neoplasms - blood - diagnosis - pathology
 
dc.subject.meshProteomics - methods
 
dc.subject.meshTumor Markers, Biological - blood
 
dc.subject.meshVimentin - blood
 
dc.subjectAFP
 
dc.subjectBiomarker
 
dc.subjectCancer screening
 
dc.subjectHCC
 
dc.subjectTumor detection
 
dc.subjectTumor size
 
dc.titleProteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (≤2 cm)
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Sun, S</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Lee, NP</contributor.author>
<contributor.author>Yeung, C</contributor.author>
<contributor.author>Chan, KL</contributor.author>
<contributor.author>Ng, IOL</contributor.author>
<contributor.author>Day, PJR</contributor.author>
<contributor.author>Luk, JM</contributor.author>
<date.accessioned>2010-09-06T09:43:54Z</date.accessioned>
<date.available>2010-09-06T09:43:54Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Journal Of Proteome Research, 2010, v. 9 n. 4, p. 1923-1930</identifier.citation>
<identifier.issn>1535-3893</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/88478</identifier.uri>
<description.abstract>Small hepatocellular carcinomas (HCCs) can be effectively cured by surgery with good clinical outcomes. However, the conventional AFP marker is ineffective in detecting small tumors. Here we employed a proteomic profiling approach to identify a candidate marker for HCC (&#8804;2 cm) in tumor tissues and then evaluate its clinical feasibility in patients? sera. The study was divided into 2 phases. (i) Biomarker discovery: we collected 76 frozen liver tissues (40 HCC and 36 controls) for proteomics profiling. Candidate protein markers were identified by MALDI-TOF/TOF and confirmed by immunoblot and qPCR. (ii) Clinical evaluation: Selected biomarker was tested by ELISA for sensitivity and specificity using serum samples from a separate cohort of 152 subjects (88 HCC and 64 controls). Vimentin was found significantly overexpressed in HCC, in particular the small-size subgroup (&#8804;2 cm) with p &lt; 0.01. When tested in the serum samples, vimentin level was significantly higher in small tumors than the non-neoplastic controls (AUC = 0.69 and p &lt; 0.01). Further analysis suggested that elevated circulating vimentin level could detect small HCC at 40.91% sensitivity and 87.50% specificity. Moreover, vimentin was found to be superior to serum AFP assayed at different cut-offs in detecting small tumors. When combined with AFP, the detection sensitivity and specificity could be further enhanced to 58.77 and 98.15%, respectively. In conclusion, serum vimentin is a potential surrogate marker, either alone or in combination with AFP, for detection of small HCCs. &#169; 2010 American Chemical Society.</description.abstract>
<language>eng</language>
<publisher>American Chemical Society. The Journal&apos;s web site is located at http://pubs.acs.org/journals/jprobs</publisher>
<relation.ispartof>Journal of Proteome Research</relation.ispartof>
<subject>AFP</subject>
<subject>Biomarker</subject>
<subject>Cancer screening</subject>
<subject>HCC</subject>
<subject>Tumor detection</subject>
<subject>Tumor size</subject>
<subject.mesh>Carcinoma, Hepatocellular - blood - diagnosis - pathology</subject.mesh>
<subject.mesh>Liver Neoplasms - blood - diagnosis - pathology</subject.mesh>
<subject.mesh>Proteomics - methods</subject.mesh>
<subject.mesh>Tumor Markers, Biological - blood</subject.mesh>
<subject.mesh>Vimentin - blood</subject.mesh>
<title>Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (&#8804;2 cm)</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1535-3893&amp;volume=9&amp;issue=4&amp;spage=1923&amp;epage=1930&amp;date=2010&amp;atitle=Proteomics+of+hepatocellular+carcinoma:+serum+vimentin+as+a+surrogate+marker+for+small+tumors+(&#8804;2+cm)</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1021/pr901085z</identifier.doi>
<identifier.pmid>20121168</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77950647292</identifier.scopus>
<identifier.hkuros>169635</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77950647292&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>9</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>1923</identifier.spage>
<identifier.epage>1930</identifier.epage>
<identifier.isi>WOS:000276215700028</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. University of Manchester
  2. The University of Hong Kong
  3. National University of Singapore